Free Trial
→ Elon will prove them wrong again (From Paradigm Press) (Ad)tc pixel
NASDAQ:KZIA

Novogen Q2 2026 Earnings Results & Report

Novogen logo
$6.91 -1.13 (-14.05%)
As of 03:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novogen reported Q2 2026 earnings on February 14, 2026. The company reported EPS of -$1.34, while revenue was $4.89 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Novogen EPS Results

Actual EPS
-$1.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novogen Revenue Results

Actual Revenue
$4.89 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Novogen Q2 2026 Earnings FAQ

Novogen (NASDAQ:KZIA) reported earnings of -$1.34 per share for Q2 2026. The report was announced on Saturday, February 14, 2026.

Novogen reported revenue of $4.89 million for Q2 2026.

Novogen Earnings Headlines

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
September 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-sovargen-co-doses-first-patient-in-phase-1b2a-trial-of-paxalisib-for-rare-seizure-disorders-302883753.html
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
September 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-announces-first-patient-dosed-in-pnoc035-clinical-study-evaluating-paxalisib-for-recurrent-pediatric-atrt-brain-cancer-302873103.html
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
October 14 at 1:00 AM  |  Porter & Company (Ad)
Kazia Therapeutics Limited (KZIA) Discusses Clinical and Corporate Updates With Focus on Paxalisib Programs in Breast and Colorectal Cancer Transcript
September 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943248-kazia-therapeutics-limited-kzia-discusses-clinical-and-corporate-updates-with-focus-on
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
September 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-colorectal-cancer-and-enhances-response-to-immunotherapy-302865533.html
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-paxalisib-clinical-trial-into-hrher2--breast-cancer-supported-by-preclinical-data-showing-strong-clinical-activity-and-safety-in-hr-breast-cancer-302865460.html
See More Novogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email.

About Novogen

Novogen (NASDAQ:KZIA) was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.

Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.

In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA. Kazia continued to focus on oncology, including the development of paxalisib, an investigational PI3K/mTOR pathway inhibitor for cancers such as glioblastoma. The company is headquartered in Australia and has conducted development activities through international clinical and research collaborations.

View Novogen Profile
Earnings Tools